December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Krystal Biotech, Inc. - Common Stock (NQ:KRYS)

187.68 -3.10 (-1.62%)
Streaming Delayed Price Updated: 11:44 AM EDT, Oct 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Krystal Biotech, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
This Krystal Biotech Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
 
Via Benzinga
A Glimpse Into The Expert Outlook On Krystal Biotech Through 9 Analysts
 
Via Benzinga
Earnings Scheduled For February 19, 2025
 
Via Benzinga
Looking Into Krystal Biotech's Recent Short Interest
 
Via Benzinga
Eliminating Some Screened Stocks
Commodity prices regularly swing 25-30% or more in any given year. When this happens, the financial health of these firms can get dicey very quickly, given the amount of capital investment it requires... 
Via Talk Markets
Topics Stocks / Equities
(KRYS) - Analyzing Krystal Biotech's Short Interest
 
Via Benzinga
Here's How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years
 
Via Benzinga
Here's How Much $1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today
 
Via Benzinga
Here's How Much $100 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today
 
Via Benzinga
Expert Ratings For Krystal Biotech
 
Via Benzinga
Earnings Scheduled For May 6, 2025
 
Via Benzinga
Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease
Abeona's Zevaskyn secures timely FDA nod, priced at $3.1 million, with 2025 sales now forecast at $31.6 million and peak U.S. revenue projected at $600 million. 
Via Benzinga
Here's How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years
 
Via Benzinga
Demystifying Krystal Biotech: Insights From 7 Analyst Reviews
 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
 
Via Benzinga
If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today
 
Via Benzinga
Is the Market Bullish or Bearish on Krystal Biotech?
 
Via Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today
 
Via Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth $400 Today
 
Via Benzinga
$100 Invested In Krystal Biotech 5 Years Ago Would Be Worth This Much Today
 
Via Benzinga
$1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Here's How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years
 
Via Benzinga
Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday
 
Via Benzinga
How Is The Market Feeling About Krystal Biotech?
 
Via Benzinga
Here's How Much $1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today
 
Via Benzinga
Here's How Much $1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today
 
Via Benzinga
(KRYS) - Analyzing Krystal Biotech's Short Interest
 
Via Benzinga
Here's How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years
 
Via Benzinga
KRYS Stock Earnings: Krystal Biotech Beats EPS, Beats Revenue for Q2 2024
KRYS stock results show that Krystal Biotech beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.